

# Duncan J Campbell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5696365/publications.pdf>

Version: 2024-02-01

83  
papers

3,421  
citations

126708

33  
h-index

143772

57  
g-index

83  
all docs

83  
docs citations

83  
times ranked

3715  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mice with Cardiac-Restricted Angiotensin-Converting Enzyme (ACE) Have Atrial Enlargement, Cardiac Arrhythmia, and Sudden Death. <i>American Journal of Pathology</i> , 2004, 165, 1019-1032.	1.9	234
2	Losartan Increases Bradykinin Levels in Hypertensive Humans. <i>Circulation</i> , 2005, 111, 315-320.	1.6	172
3	Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement. <i>Clinical Chemistry</i> , 2009, 55, 867-877.	1.5	172
4	The Site of Angiotensin Production. <i>Journal of Hypertension</i> , 1985, 3, 199-207.	0.3	153
5	Effects of Losartan on Angiotensin and Bradykinin Peptides and Angiotensin-Converting Enzyme. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 233-240.	0.8	143
6	The Kallikrein-Kinin System In Humans. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 1060-1065.	0.9	135
7	Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke. <i>Stroke</i> , 2005, 36, 2143-2147.	1.0	123
8	The renin-angiotensin and the kallikrein-kinin systems. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 784-791.	1.2	121
9	Long-term neprilysin inhibition – implications for ARNIs. <i>Nature Reviews Cardiology</i> , 2017, 14, 171-186.	6.1	111
10	Angiotensin and Bradykinin Peptides in the TGR(mRen-2)27 Rat. <i>Hypertension</i> , 1995, 25, 1014-1020.	1.3	100
11	An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. <i>Journal of Hypertension</i> , 1990, 8, 715-724.	0.3	92
12	Critical Review of Prorenin and (Pro)renin Receptor Research. <i>Hypertension</i> , 2008, 51, 1259-1264.	1.3	85
13	Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice. <i>Hypertension</i> , 2004, 43, 854-859.	1.3	84
14	Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. <i>Journal of Hypertension</i> , 2004, 22, 1971-1976.	0.3	77
15	Angiotensin Peptides in Spontaneously Hypertensive and Normotensive Donryu Rats. <i>Hypertension</i> , 1995, 25, 928-934.	1.3	75
16	β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. <i>Lancet</i> , The, 2001, 358, 1609-1610.	6.3	72
17	Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease. <i>Circulation</i> , 2005, 112, 110-116.	1.6	71
18	Interpretation of Plasma Renin Concentration in Patients Receiving Aliskiren Therapy. <i>Hypertension</i> , 2008, 51, 15-18.	1.3	62

#	ARTICLE	IF	CITATIONS
19	RLLKKMPSV Influences the Vasculature, Neurons and Glia, and (Pro)Renin Receptor Expression in the Retina. <i>Hypertension</i> , 2010, 55, 1454-1460.	1.3	61
20	Characterization of angiotensin peptides in plasma of anephric man. <i>Journal of Hypertension</i> , 1991, 9, 265-266.	0.3	54
21	AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F1024-F1033.	1.3	54
22	Clinical Relevance of Local Renin Angiotensin Systems. <i>Frontiers in Endocrinology</i> , 2014, 5, 113.	1.5	54
23	Kinins in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 278, R897-R904.	0.9	52
24	Neprilysin Inhibitors and Bradykinin. <i>Frontiers in Medicine</i> , 2018, 5, 257.	1.2	51
25	Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. <i>European Heart Journal</i> , 2005, 26, 1910-1915.	1.0	47
26	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2011, 10, 80.	2.7	47
27	Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. <i>Hypertension</i> , 2011, 57, 186-192.	1.3	45
28	Obesity Is Associated with Lower Coronary Microvascular Density. <i>PLoS ONE</i> , 2013, 8, e81798.	1.1	45
29	Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels. <i>PLoS ONE</i> , 2012, 7, e49813.	1.1	44
30	Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro- $\beta$ -Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease. <i>Archives of Neurology</i> , 2006, 63, 60.	4.9	41
31	Prediction of Heart Failure by Amino Terminal-pro- $\beta$ -Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease. <i>Hypertension</i> , 2005, 45, 69-74.	1.3	39
32	Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. <i>Open Heart</i> , 2018, 5, e000782.	0.9	39
33	Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. <i>Journal of Hypertension</i> , 2005, 23, 945-954.	0.3	36
34	Heart failure: how can we prevent the epidemic?. <i>Medical Journal of Australia</i> , 2003, 179, 422-425.	0.8	32
35	Angiotensin-Converting Enzyme Inhibition Modifies Angiotensin but Not Kinin Peptide Levels in Human Atrial Tissue. <i>Hypertension</i> , 1999, 34, 171-175.	1.3	31
36	The Peripheral Renin-Angiotensin System Is Not Involved In The Hypertension Of Sheep Exposed To Prenatal Dexamethasone. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 306-311.	0.9	31

#	ARTICLE	IF	CITATIONS
37	The Operating Surgeon Is an Independent Predictor of Chest Tube Drainage Following Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 242-246.	0.6	31
38	Plasma amino-terminal pro-brain natriuretic peptide: A novel approach to the diagnosis of cardiac dysfunction. <i>Journal of Cardiac Failure</i> , 2000, 6, 130-139.	0.7	31
39	Plasma amino-terminal pro-brain natriuretic peptide: A novel approach to the diagnosis of cardiac dysfunction. <i>Journal of Cardiac Failure</i> , 2000, 6, 130-139.	0.7	30
40	Cellophane Perinephritis Hypertension and Its Reversal in Rabbits. <i>Circulation Research</i> , 1973, 33, 105-112.	2.0	28
41	Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans. <i>Hypertension</i> , 2003, 41, 482-487.	1.3	28
42	Prorenin Contributes to Angiotensin Peptide Formation in Transgenic Rats With Rat Prorenin Expression Targeted to the Liver. <i>Hypertension</i> , 2009, 54, 1248-1253.	1.3	27
43	Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 623-631.	0.9	23
44	Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 537-548.	0.9	22
45	Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H659-H667.	1.5	21
46	Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 1027-1037.	0.8	21
47	Noninvasive Cardiac Imaging and the Prediction of Heart Failure Progression in Preclinical Stage A/B Subjects. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1504-1519.	2.3	21
48	Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1594-1602.	0.8	21
49	Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort. <i>European Journal of Heart Failure</i> , 2019, 21, 449-459.	2.9	21
50	Do intravenous and subcutaneous angiotensin <math>\text{II}</math> increase blood pressure by different mechanisms?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 560-570.	0.9	19
51	Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. <i>Open Heart</i> , 2015, 2, e000278.	0.9	15
52	Increased Angiotensin II-Induced Hypertension and Inflammatory Cytokines in Mice Lacking Angiotensin-Converting Enzyme N Domain Activity. <i>Hypertension</i> , 2012, 59, 283-290.	1.3	13
53	NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: Results of the SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF). <i>International Journal of Cardiology</i> , 2013, 169, 133-138.	0.8	13
54	A review of Perindopril in the reduction of cardiovascular events. <i>Vascular Health and Risk Management</i> , 2006, 2, 117-124.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Angiotensin II generation in vivo: does it involve enzymes other than renin and angiotensin-converting enzyme?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 314-316.	1.0	12
56	Hypertension in the (mRen-2) <sup>27</sup> Rat Is Not Explained by Enhanced Kinetics of Transgenic Ren-2 Renin. Hypertension, 2003, 42, 523-527.	1.3	11
57	CAN MEASUREMENT OF B-type NATRIURETIC PEPTIDE LEVELS IMPROVE CARDIOVASCULAR DISEASE PREVENTION?. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 442-446.	0.9	11
58	Age-related longitudinal change in cardiac structure and function in adults at increased cardiovascular risk. ESC Heart Failure, 2020, 7, 1344-1361.	1.4	11
59	L-NAME hypertension: trying to fit the pieces together. Journal of Hypertension, 2006, 24, 33-36.	0.3	10
60	(Pro)renin Receptor: A Treatment Target for Diabetic Retinopathy?. Diabetes, 2009, 58, 1485-1487.	0.3	10
61	Risk factor management in a contemporary Australian population at increased cardiovascular disease risk. Internal Medicine Journal, 2018, 48, 688-698.	0.5	10
62	Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. Journal of Hypertension, 2007, 25, 699-705.	0.3	8
63	Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 413-418.	3.1	6
64	Vaccination Against High Blood Pressure. Current Pharmaceutical Design, 2012, 18, 1005-1010.	0.9	6
65	Age-specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure. ESC Heart Failure, 2019, 6, 747-757.	1.4	6
66	The clinical utility curve: a proposal to improve the translation of information provided by prediction models to clinicians. BMC Research Notes, 2016, 9, 219.	0.6	5
67	Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function. BMC Nephrology, 2021, 22, 152.	0.8	5
68	Mis-reporting of energy intake among older Australian adults: Prevalence, characteristics, and associations with quality of life. Nutrition, 2021, 90, 111259.	1.1	5
69	Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure. ESC Heart Failure, 2021, , .	1.4	5
70	Angiotensin vaccination: What is the prospect of success?. Current Hypertension Reports, 2009, 11, 63-68.	1.5	4
71	GENETIC MODELS PROVIDE UNIQUE INSIGHT INTO ANGIOTENSIN AND BRADYKININ PEPTIDES IN THE EXTRAVASCULAR COMPARTMENT OF THE HEART <i>IN VIVO</i> . Clinical and Experimental Pharmacology and Physiology, 2009, 36, 547-553.	0.9	2
72	Amino-terminal-pro-B-type natriuretic peptide levels and low diastolic blood pressure. Journal of Hypertension, 2014, 32, 2158-2165.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Letter by Campbell Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction" Circulation, 2015, 132, e205.	1.6	2
74	Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?. BMC Cardiovascular Disorders, 2016, 16, 221.	0.7	2
75	Quality of life and associations with health-related behaviours among older adults with increased cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1146-1153.	1.1	2
76	Putting blood pressure in its place. Journal of Hypertension, 2007, 25, 921-923.	0.3	1
77	Introduction. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 525-526.	0.9	1
78	Primary prevention of cardiovascular disease: new guidelines, technologies and therapies. Medical Journal of Australia, 2014, 200, 146-148.	0.8	1
79	Response to the Renin Rise With Aliskiren: It's Simply Stoichiometry. Hypertension, 2008, 51, .	1.3	0
80	Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease. Journal of Hypertension, 2010, 28, 1429-1437.	0.3	0
81	Not much need for ambulatory blood pressure monitoring. Medical Journal of Australia, 2012, 196, 241-241.	0.8	0
82	Therapeutic modulation of tissue kallikrein expression. Biological Chemistry, 2016, 397, 1293-1297.	1.2	0
83	Letter by Campbell Regarding Article, "CD4 <sup>+</sup> T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury" Circulation, 2017, 136, 2198-2199.	1.6	0